Alendronate Sodium Tablet
Product Images NDC 50090-5474

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Alendronate Sodium (NDC 50090-5474). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1 (Alendronate Fig1)

Figure 1 (Alendronate Fig1)
FDA Label Image

Figure 2 (Alendronate Fig2)

Figure 2 (Alendronate Fig2)
FDA Label Image

Figure 3 (Alendronate Fig3)

Figure 3 (Alendronate Fig3)
This appears to be a chart showing the mean percent change from baseline in lumbar spine bone mineral density (BMD) in postmenopausal women treated with alendronate 10 mg/day versus placebo over a period of 36 months. The study is a multinational study, and the chart shows the effect of the treatment over time, with months plotted along the x-axis and the percent change in BMD plotted along the y-axis.*
FDA Label Image

Figure 4 (Alendronate Fig4)

Figure 4 (Alendronate Fig4)
FDA Label Image

Studies In Glucocorticoid (Treated Patients Increase in BMD Alendronate 5 mg/day at One Year)

Studies In Glucocorticoid (Treated Patients Increase in BMD Alendronate 5 mg/day at One Year)
FDA Label Image

Studies In Paget's Disease Of Bone Effect On Serum Alkaline Phosphatase Of Alendronate 40 mg/day Versus Placebo Or Etidronate 400 mg/day (Alendronate Fig6)

Studies In Paget's Disease Of Bone Effect On Serum Alkaline Phosphatase Of Alendronate 40 mg/day Versus Placebo Or Etidronate 400 mg/day (Alendronate Fig6)
The text provides information on the effect of Alendronate 40mg/day on serum alkaline phosphatase in Paget’s disease of bone compared to Placebo or Etidronate 400mg/day through a multinational and US study conducted over a period of 6 months. It also shows a mean % change from Baseline.*
FDA Label Image

Chemical Structure (Alendronate Str)

Chemical Structure (Alendronate Str)
FDA Label Image

Label Image (Lbl500905474)

Label Image (Lbl500905474)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.